Transcript Good Manufacturing Practices for Pharmaceuticals

GOOD MANUFACTURING
PRACTICES FOR
PHARMACEUTICALS
By
Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D
Department of Pharmaceutics
Omar Al-Mukthar University
Al-Bayda, Libya.
E-mail: [email protected]
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
1
CONTENTS
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Current GMP in manufacturing processes
Packaging and holding of drugs
Finished pharmaceuticals
General provisions
Organization and personnel
Building and facilities
Equipment
Control of components
Containers and closures
Production and process control
Packaging and labeling control
Holding and distribution
Records and reports
Returned savaged drug products
The inspection for compliance with GMP regulations
Controlled substances safeguards
References
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
2
Introduction
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
3
What is GMP ?
• GMP is that part of Quality assurance which ensures
that the products are consistently manufactured and
controlled to the Quality standards appropriate to
their intended use
• A set of principles and procedures which, when
followed by manufacturers for therapeutic goods,
helps ensure that the products manufacture will
have the required quality.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
4
Good Manufacturing Practices
• A basic tenet of GMP is that quality cannot be
tested into a batch of product but must be
built into each batch of product during all
stages of the manufacturing process.
• It is designed to minimize the risks involved in
any pharmaceutical production that cannot be
eliminated through testing the final product.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
5
Some of the main risks are
– unexpected contamination of products, causing
damage to health or even death.
– incorrect labels on containers, which could mean
that patients receive the wrong medicine.
– insufficient or too much active ingredient,
resulting in ineffective treatment or adverse
effects.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
6
Why GMP is important
• A poor quality medicine may contain toxic
substances that have been unintentionally added.
• A medicine that contains little or none of the claimed
ingredient will not have the intended therapeutic
effect.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
7
GMP
QA
GMP
QC
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
8
QA, GMP & QC inter-relationship
QA
It is the sum total of the
organized arrangements with
the objective of ensuring that
products will be of the quality
required for their intended use
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
9
GMP
GMP
Is that part of Quality
Assurance aimed at
ensuring that products are
consistently manufactured
to a quality appropriate to
their intended use
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
10
QA, GMP & QC inter-relationship
QC
Is that part of GMP concerned with
sampling, specification & testing,
documentation & release
procedures which ensure that the
necessary & relevant tests are
performed & the product is released
for use only after ascertaining it’s
quality
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
11
QC and QA
• QC is that part of GMP which • QA is the sum total of
is concerned with sampling,
organized
specifications, testing and
arrangements made
with in the organization,
with the object of
documentation,and release
ensuring that product
procedures which ensure
will be of the Quality
that the necessary and
required by their
relevant tests are carried out
intended use.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
12
QC and QA
• Operational laboratory
techniques and
activities used to fulfill
the requirement of
Quality
2014/01/12
• All those planned or
systematic actions
necessary to provide
adequate confidence
that a product will
satisfy the requirements
for quality
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
13
QC and QA
• QC is lab based
2014/01/12
• QA is company based
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
14
GMP
• The Quality of a formulation or a bulk drug
depends on the Quality of those producing it
• GMP is the magic key that opens the door of
the Quality
• In matter of GMP, swim with the current and
in matter of Quality stand like a rock!
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
15
GMP helps boost pharmaceutical
export opportunities
• Most countries will only accept import and
sale of medicines that have been
manufactured to internationally recognized
GMP.
• Governments seeking to promote their
countries export of pharmaceuticals can do so
by making GMP mandatory for all
pharmaceutical production and by training
their inspectors in GMP requirements.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
16
GMP Covers…
• ALL aspects of production; from the starting materials,
premises and equipment to the training and personal
hygiene of staff.
• Detailed, written procedures are essential for each
process that could affect the quality of the finished
product.
• There must be systems to provide documented proof
that correct procedures are consistently followed at
each step in the manufacturing process - every time a
product is made.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
17
GMP guidelines
•
•
•
•
•
•
GMP as per Schedule “M”
GMP as per WHO
GMP as per MCA now known as MHRA
GMP as per TGA
GMP as per US FDA
GMP as per ICH guidelines
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
18
GMP guidelines
• GMP as per Schedule “M”
www.cdsco.nic.in
• GMP as per WHO
www.who.int
• GMP as per MCA now known as MHRA
www.mca.gov.uk
• GMP as per TGA
www.tga.gov.au
• GMP as per US FDA
www.fda.gov
• GMP as per ICH guidelines
www.ich.org
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
19
GMP guidance documents
• EU Good Manufacturing Practice (GMP)
Guidelines, Volume 4 of “The rules governing
medicinal products in the European Union”
• US FDA current Good Manufacturing Practice
(cGMP) for finished pharmaceuticals, 21 CFR, 210
and 211
• WHO Good Manufacturing Practices for
pharmaceutical products, Annex 4 to WHO
Technical Report Series, No. 908, 2003
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
20
GMP
•
•
•
•
•
•
•
GMP in solid dosage forms
GMP in semisolid dosage forms
GMP in Liquid orals
GMP in Parenterals Production
GMP in Ayurvedic medicines
GMP in Bio technological products
GMP in Nutraceuticals and cosmeceuticals
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
21
Ten Principles of GMP
1.
Design and construct the facilities and equipments
properly
2. Follow written procedures and Instructions
3. Document work
4. Validate work
5. Monitor facilities and equipment
6. Write step by step operating procedures and work on
instructions
7. Design ,develop and demonstrate job competence
8. Protect against contamination
9. Control components and product related processes
10. Conduct planned and periodic audits
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
22
List of important documents
in GMP
•
•
•
•
•
•
•
•
•
•
Policies
SOP
Specifications
MFR (Master Formula Record)
BMR
Manuals
Master plans/ files
Validation protocols
Forms and Formats
Records
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
23
10 attributes of a good document
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
Accurate
Clear
Complete
Consistent
Indelible
Legible
Timely
Direct
Authentic
Authorized
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
24
Beyond GMP
• Reduce pollution - Zero discharge
• Adaptation of environment friendly methods
• Consideration for better and healthier life tomorrow
• Consideration of ethics in life
• One should begin with end in mind otherwise it will be
the beginning of the end
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
25
API Manufacturing Process
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
26
Secondary Manufacturing
Dosage Forms
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
27
Secondary Manufacturing
Process - Tablets
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
28
Secondary Manufacturing Process –
Sterile parenteral for injection
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
29
Biotechnology Manufacturing
Process
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
30
Current GMP in manufacturing
processes (cGMP)
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
31
What are cGMPs?
• cGMP refers to the Current Good Manufacturing
Practice regulations enforced by the US Food and
Drug Administration (FDA).
• cGMP provide for systems that assure proper design,
monitoring and control of manufacturing processes
and facilities.
• Adherence to the cGMP regulations assures the
identity, strength, quality and purity of drug products
by requiring that manufacturers of medications
adequately control manufacturing operations
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
32
What are cGMPs?
• This includes establishing strong quality management
systems, obtaining appropriate quality raw materials,
establishing robust operating procedures, detecting
and investigating product quality deviations, and
maintaining reliable testing laboratories.
• This formal system of controls at a pharmaceutical
company, if adequately put into practice, helps to
prevent instances of contamination, mix-ups,
deviations, failures, and errors.
• This assures that drug products meet their quality
standards.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
33
What are cGMPs?
• The cGMP requirements were established to be
flexible in order to allow each manufacturer to
decide individually how to best implement the
necessary controls by using scientifically sound
design, processing methods, and testing
procedures.
• The flexibility in these regulations allows
companies to use modern technologies and
innovative approaches to achieve higher quality
through continual improvement.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
34
What are cGMPs?
• Accordingly the “c” in cGMP stands for
“current” requiring companies to use
technologies and systems that are up-to-date
in order to company with the regulations.
• Systems and equipment that may have been
“top-of-the-line” to prevent contamination,
mix-ups, and errors 10 or 20 years ago may be
less than adequate by today’s standards.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
35
What are cGMPs?
• It is important to note that cGMP are
minimum requirements.
• Many pharmaceutical manufacturers are
already
implementing
comprehensive,
modern quality systems and risk management
approaches that exceed these minimum
standards.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
36
Why are cGMP so important
• A consumer usually cannot detect (through smell,
touch, or sight) that a drug product is safe or if it will
work.
• While cGMPs require testing, testing alone is not
adequate to ensure quality.
• In most instances testing is done on a small sample
of a batch (for example, a drug manufacturer may
test 1000 tablets from a batch that contains 2 million
tablets), so that most of the batch can be used for
patients rather than destroyed by testing.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
37
Why are cGMP so important
• Therefore, it is important that drugs are
manufactured under conditions and practices
required by the cGMP regulations to assure that
quality is built into the design and manufacturing
process at every step.
• Facilities that are in good conditions, equipment that
is properly maintained and calibrated, employees
who are qualified and fully trained, and processes
that are reliable and reproducible, are a few
examples of how cGMP requirements help to assure
the safety and efficacy
of
drug
products.
Department of Pharmaceutics, Omar Al2014/01/12
Mukthar University, Al-Bayda, Libya.
38
Packaging
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
39
Packaging
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
40
Packaging
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
41
Packaging and holding of
drugs
• Care shall be taken when using automatic
tablet and capsule counting, strip and blister
packaging equipment to ensure that all
‘rogue’ tablets, capsules or foils from
packaging operation are removed before a
new packaging operation is commenced.
• There shall be an independent recorded check
of the equipment before a new batch of
tablets or capsules is handled.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
42
Packaging and holding of
drugs
• Uncoated tablets shall be packed on
equipment designed to minimize the risk of
cross-contamination. Such packaging shall be
carried out in an isolated area when potent
tablets or Beta-Iactum containing tablets are
being packed.
• The strips coming out of the machine shall be
inspected for defects such as misprint, cuts on
the foil, missing tablets and improper sealing.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
43
Packaging and holding of
drugs
• Integrity of individual packaging strips and
blisters shall be subjected to vacuum test
periodically to ensure leak proofness of each
pocket strip and blister and records
maintained.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
44
Finished pharmaceuticals
Appropriate specifications for finished products
shall include: • The designated name of the product and the
code reference.
• The formula or a reference to the formula and
the pharmacopoeial reference.
• Directions for sampling and testing or a reference
to procedures.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
45
Finished pharmaceuticals
• A description of the dosage form and package
details.
• The qualitative and quantitative requirements,
with the acceptance limits for release.
• The storage conditions and precautions,
where applicable, and the shelf-life.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
46
General provisions
• The processing of dry materials and products
creates problems of dust control and crosscontamination. Special attention is therefore,
needed in the design, maintenance and use of
premises and equipment in order to overcome
these problems. Wherever required, enclosed
dust control manufacturing systems shall be
employed.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
47
General provisions
• Suitable environmental conditions for the
products handled shall be maintained by
installation of air-conditioning wherever
necessary. Effective air extraction systems,
with discharge points situated to avoid
contamination of other products and
professes shall be provided. Filters shall be
installed to retain dust and protect the factory
and local environment
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
48
General provisions
• Special care shall be taken to protect against
subsequent contamination of the product by
particles of metal or wood. The use of metal
detector
is
recommended.
Wooden
equipment should be avoided. Screens, sieves,
punches and dies shall be examined for wear
and tear or for breakage before and after each
use.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
49
General provisions
• All ingredients for a dry product shall be sifted before
use unless the quality of the input material can be
assured. Such sifting shall normally be carried out at
dedicated areas.
• Where the facilities are designed to provide special
environmental conditions of pressure differentials
between rooms, these conditions shall be regularly
monitored and any specification results brought to
the immediate attention of the Production and
quality Assurance Department which shall be
immediately attended
to.
Department of Pharmaceutics, Omar Al2014/01/12
Mukthar University, Al-Bayda, Libya.
50
General provisions
• Care shall be taken to guard against any
material lodging and remaining undetected in
any processing or packaging equipment.
Particular care shall be taken to ensure that
any vacuum, compressed air or air-extraction
nozzles are kept clean and that there is no
evidence lubricants leaking into the product
from any part of the equipment.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
51
Organization and personnel
1. Responsibilities of quality control unit.
2. Personnel qualifications.
3. Personnel responsibilities.
4. Consultants.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
52
Organization and personnel
• The manufacture shall be conducted under the direct
supervision of competent technical staff with
prescribed qualifications and practical experience in
the relevant dosage and/or active pharmaceutical
products.
• The head of the Quality Control Laboratory shall be
independent of the manufacturing unit. The testing
shall be conducted under the direct supervision of
competent technical staff who shall be whole time
employees of the licensee.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
53
Organization and personnel
• Personnel for Quality Assurance and Quality Control
operations shall be suitably qualified and experienced.
• Written duties of technical and Quality Control personnel shall
be laid and following strictly.
• Number of personnel employed shall be adequate and in
direct proportion to the workload.
• The licensee shall ensure in accordance with a written
instruction that all personnel in production area or into
Quality Control Laboratories shall receive training appropriate
to the duties and responsibility assigned to them. They shall
be provided with regular in-service training.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
54
Building and facilities
1. Design and construction features.
2. Lighting.
3. Ventilation, air filtration, air heating and
cooling.
4. Plumbing.
5. Sewage and refuse.
6. Washing and toilet facilities.
7. Sanitation.
8. Maintenance.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
55
Building and facilities
• The building(s) used for the factory shall be
designed,
constructed,
adapted
and
maintained to suit the manufacturing
operations so as to permit production of drugs
under hygienic conditions. They shall conform
to the conditions laid down in the Factories
Act.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
56
Building and facilities
• The premises used for manufacturing,
processing, warehousing, packaging labeling
and testing purposes.
• Compatible with other drug manufacturing
operations that may be carried out in the
same or adjacent area / section.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
57
Building and facilities
• Adequately provided with working space to allow
orderly and logical placement of equipment,
materials and movement of personnel so as to:
 avoid the risk of mix-up between different
categories of drugs or with raw materials,
intermediates and in-process material.
 avoid the possibilities of contamination and
cross- contamination by providing suitable
mechanism.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
58
Building and facilities
• Designed/constructed/maintained to prevent
entry of insects, pests, birds, vermins, and
rodents. Interior surface (walls, floors and
ceilings) shall be smooth and free from cracks,
and permit easy cleaning, painting and
disinfection.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
59
Building and facilities
• Air-conditioned, where prescribed for the operations and
dosage froms under production. The production and
dispensing areas shall be well lighted, effectively ventilated,
with air control facilities and may have proper Air Handling
Units (wherever applicable) to maintain conditions including
temperature and, wherever necessary, humidity, as defined
for the relevant product. These conditions shall be
appropriate to the category of drugs and nature of the
operation. These shall also be suitable to the comforts of the
personnel working with protective clothing, products handled,
operations undertaken within them in relation to the external
environment. These areas shall be regularly monitored for
compliance with required specifications;
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
60
Building and facilities
• Provided with drainage system, as specified
for the various categories of products, which
shall be of adequate size and so designed as to
prevent back flow and/or prevent insects and
rodents entering the premises. Open channels
shall be avoided in manufacturing areas and,
where provided, these shall be shallow to
facilitate cleaning and disinfection;
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
61
Building and facilities
• The walls and floors of the areas where
manufacture of drugs is carried out shall be
free from cracks and open joints to avoid
accumulation of dust. These shall be smooth,
washable, covered and shall permit easy and
effective cleaning and dis-infection. The
interior surfaces shall not shed particles. A
periodical record of cleaning and painting of
the premises shall be maintained.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
62
Equipment
1.
2.
3.
4.
Equipment design, size, and location.
Equipment construction.
Equipment cleaning and maintenance.
Automatic, mechanical, and electronic
equipment.
5. Filters.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
63
Equipment
• Equipment shall be located, designed,
constructed, adapted and maintained to suit the
operations to be carried out. The layout and
design of the equipment shall aim to minimise
the risk of errors and permit effective cleaning
and maintenance in order to avoid crosscontamination, build-up of dust or dirt and, in
general any adverse effect on the quality of
products. Each equipment shall be provided with
a logbook, wherever necessary.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
64
Equipment
• Balances and other measuring equipment of
an appropriate range, accuracy and precision
shall be available in the raw material stores,
production and in process control operations
and these shall be calibrated and checked on a
scheduled basis in accordance with Standard
Operating
Procedures
and
records
maintained.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
65
Equipment
• The parts of the production equipment that come
into contact with the product shall not be
reactive, additive or adsorptive to an extent that
would affect the quality of the product.
• To avoid accidental contamination, wherever
possible, non-toxic/edible grade lubricants shall
be used and the equipment shall be maintained
in a way that lubricants do not contaminate the
products being produced.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
66
Equipment
• Defective equipment shall be removed from
production and Quality Control areas or
appropriately labeled.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
67
Control of components
1. General requirements.
2. Receipt & storage of untested components, drug
product containers, and closures.
3. Testing and approval or rejection of components,
drug product containers, and closures.
4. Use of approved components, drug product
containers, and closures.
5. Retesting of approved components, drug product
containers, and closures.
6. Rejected components, drug product containers,
and closures.
7. Drug product containers and closures.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
68
Control of components
• Each tablets compressing machine shall be
provided with effective dust control facilities
to avoid cross-contamination. Unless the same
product is being made on each machine, or
unless the compression machine itself
provides its own enclosed air controlled
environment, the machine shall be installed in
separate cubicles.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
69
Control of components
• Suitable physical procedural and labeling
arrangements shall be made to prevent mix
up of materials, granules and tables on
compression machinery.
• Accurate and calibrated weighting equipment
shall be readily available and used for inprocess monitoring of tablet weight variation.
Procedures used shall be capable of detecting
out-of-limits tablets.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
70
Control of components
• At the commencement of each compression run and
in case of multiple compression points in a
compression machine, sufficient individual tablets
shall be examined at fixed intervals to ensure that a
tablet from each compression station or from each
compression point has been inspected for suitable
pharmacopoeial parameters like ‘appearance’,
‘weight variation’, ‘disintegration’, ‘hardness’,
‘friability’ and ‘thickness’. The results shall be
recorded as part of the batch documentation.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
71
Control of components
• Tablets shall be de-dusted, preferably by
automatic device and shall be monitored for
the presence of foreign materials besides any
other defects.
• Tablets shall be collected into clean, labeled
containers.
• Rejected or discarded tablets shall be isolated
in identified containers and their quality
recorded in the Batch Manufacturing Record.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
72
Control of components
• In-process control shall be employed to ensure that
the products remain within specification. During
compression, samples of tablets shall be taken at
regular intervals of not greater than 30 minutes to
ensure that they are being produced in compliance
with specified in-process specification. The tablets
shall also be periodically checked for additional
parameters such as ‘appearance’, ‘weight variation’,
‘disintegration’, ‘hardness’, ‘friability’ and ‘thickness’
and contamination by lubricating oil.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
73
Containers and closures
• All containers and closures intended for use shall
comply with the pharmacopoeial requirements.
Suitable validated test methods, sample sizes,
specifications,
cleaning
procedure
and
sterilization procedure, wherever indicated, shall
be strictly followed to ensure that these are not
reactive, additive, absorptive, or leach to an
extent that significantly affects the quality or
purity of the drug. No second hand or used
containers and closures shall be used.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
74
Containers and closures
• Whenever bottles are being used, the written
schedule of cleaning shall be laid down and
followed. Where bottles are not dried after
washing, they should be rinsed with de-ionised
water or distilled water, as the case may be.
• For in-process and bulk products. - Specifications
for in-process material, intermediate and bulk
products shall be available. The specifications
should be authenticated.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
75
Containers and closures
• All containers and closures intended for use shall
comply with the pharmacopoeial and other specified
requirements. Suitable samples sizes, specifications,
test methods, cleaning procedures and sterilization
procedures, shall be used to assure that containers,
closures and other component parts of drug
packages are suitable and are not reactive, additive,
adsorptive or leachable or presents the risk of
toxicity to an extent that significantly affects the
quality or purity of the drug. No second hand or used
containers and closures shall be used.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
76
Containers and closures
• Plastic granules shall also comply with the
pharmacopoeial requirements including physiochemical and biological tests.
• All containers and closures shall be rinsed prior
to sterilization with Water for Injection
according to written procedure.
• The design of closures, containers and stoppers
shall be such as to make cleaning, easy and also
to make airtight seal when fitted to the bottles.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
77
Containers and closures
• It shall be ensured that containers and
closures chosen for a particular product are
such that when coming into contact they are
not absorbed into the product and they do
not affect the product adversely. The closures
and stoppers should be of such quality
substances as not to affect the quality of the
product and avoid the risk of toxicity.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
78
Containers and closures
• Whenever glass bottles are used, the written
schedule of cleaning shall be laid down and followed.
Where bottles are not dried after washing, these
shall be finally rinsed with distilled water or pyrogen
free water, as the case may be, according to written
procedure.
• Individual containers of parenteral preparations,
ophthalmic preparations shall be examined against
black/white background fitted with diffused light
after filling so as to ensure freedom from foreign
matters.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
79
Containers and closures
Glass Bottles:• Shape and design of the glass bottle shall be rational and
standardized. Glass bottles made of USP Type-I and USP
Type-II glass shall only be used. Glass bottles shall not be
reused. Before use, USP Type-II bottles shall be validated
for the absence of particulate matter generated over a
period of the shelf life of the product and shall be
regularly monitored after the production, following
statistical sampling methods. USP Type-III glass
containers may be used for non-parenteral sterile
products such as Otic Solutions.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
80
Containers and closures
Plastic Containers.• Pre-formed plastic containers intended to be used for packing
of Large Volume Parenteral shall be moulded in-house by onecontinuous operation through an automatic machine.
• Blowing, filling and sealing (plugging) operation shall be
conducted in room(s) conforming to requirements as
mentioned in Table III of Item 3.10. Entry to the area where
such operations are undertaken, shall be through a series of
airlocks. Blowers shall have an air supply which is filtered
through 0.22µ filters. Removal of runners and plugging
operations shall be conducted under a laminar airflow
workstation.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
81
Containers and closures
Rubber Stoppers:• The tuber stoppers used for Large Volume
Parenterals shall comply with specifications
prescribed in the current edition of the Indian
Pharmacopoeia.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
82
Production and process
control
1.
2.
3.
4.
5.
Written procedures; deviations.
Charge-in of components.
Calculation of yield.
Equipment identification.
Sampling and testing of in-process materials
and drug products.
6. Time limitations on production.
7. Control of microbiological contamination.
8. Reprocessing.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
83
Production and process
control
• Production control is a process of making sure
that production is constantly maintained to
produce the products of given specifications.
• Control process have several aspects, such as
raw materials, tools, in-process materials and
finished products.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
84
Production and process
control
• Production control process can be made effective by:
 Setting standards
 Measuring the job performing
 Getting feedback of results
 Taking corrective action
• Production controls are to ensure that orders are not
misunderstood, standards are not violated and
objectives are not shifted unknowing. It is a means of
building quality.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
85
Packaging and labeling
control
1.
2.
3.
4.
Materials examination and usage criteria.
Labeling issuance.
Packaging and labeling operations.
Tamper-evident packaging requirements for
over-the-counter (OTC) human drug
products.
5. Drug product inspection.
6. Expiration dating.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
86
Packaging and labeling
control
• Care shall be taken when using automatic
tablet and capsule counting, strip and blister
packaging equipment to ensure that all
‘rogue’ tablets, capsules or foils from
packaging operation are removed before a
new packaging operation is commenced.
There shall be an independent recorded check
of the equipment before a new batch of
tablets or capsules is handled.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
87
Packaging and labeling
control
• Uncoated tablets shall be packed on
equipment designed to minimize the risk of
cross-contamination. Such packaging shall be
carried out in an isolated area when potent
tablets or Beta-Iactum containing tablets are
being packed.
• The strips coming out of the machine shall be
inspected for defects such as misprint, cuts on
the foil, missing tablets and improper sealing.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
88
Packaging and labeling
control
• Integrity of individual packaging strips and
blisters shall be subjected to vacuum test
periodically to ensure leak proofness of each
pocket strip and blister and records
maintained.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
89
Packaging and labeling
control
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
90
Holding and distribution
1. Warehousing procedures.
2. Distribution procedures.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
91
Holding and distribution
• Prior to distribution or dispatch of given batch of a drug, it
shall be ensure that the batch has been duly tested, approved
and released by the quality control personnel. Pre-dispatch
inspection shall be performed on each consignment on a
random basis to ensure that only the correct goods are
dispatched. Detailed instructions for warehousing and
stocking of Large Volume Parenterals, if stocked, shall be in
existence and shall be complied with after the batch is
released for distribution. Periodic audits of warehousing
practices followed at distribution centers shall be carried out
and records thereof shall be maintained. Standard Operating
Procedures shall be developed for warehousing of products.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
92
Holding and distribution
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
93
Records and reports
1. General requirements.
2. Equipment cleaning and use log.
3. Component, drug product container, closure, and
labeling records.
4. Master production and control records.
5. Batch production and control records.
6. Production record review.
7. Laboratory records.
8. Distribution records.
9. Complaint files.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
94
Records and reports
• The licensee shall maintain records of different
manufacturing activities with regard to each
stage of manufacture in-process control,
assembling, packing, batch records for the
quantity of devices manufactured from each lot
of blended granules, duration of work, hourly
quantum of production in respect of each item as
well as record of each sterilizing cycle of the
gaseous method employed.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
95
Records and reports
• Records shall be maintained for all disposal of
waste.
• The records shall be made or completed at the
time of each operation in such a way that all
significant activities concerning the manufacture
of pharmaceutical products are traceable.
• Records and associated Standard Operating
Procedures (SOP) shall be retained for at least
one year after the expiry date of the finished
product.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
96
Records and reports
• Records of receipt of all labeling and
packaging materials shall be maintained for
each shipment received indicating receipt,
control reference numbers and whether
accepted or rejected.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
97
Records and reports
The records of the receipts shall include;
a. The name of the material on the delivery note and the
number of containers;
b. The date of receipt;
c. The manufacturer’s and/ or supplier’s name;
d. The manufacturer’s batch or reference number;
e. The total quantity, and number of containers, quantity in each
container received;
f. The control reference number assigned after receipt;
g. Any other relevant comment or information.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
98
Records and reports
The manufacturing records
• Serial number of the Batch Manufacturing Record.
• Reference to Master Formula Record.
• Filter integrity testing records
• Leak test records.
• Inspection records.
• Container washing records.
• Environmental monitoring records.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
99
Records and reports
• Reports of serious adverse drug reactions
resulting from the use of a drug along with
comments and documents shall be forthwith
reported to the concerned licensing authority.
• Reference numbers of relevant analytical
reports.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
100
Returned savaged drug
products
1. Returned drug products.
2. Drug product salvaging.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
101
Returned savaged drug
products
• Adequate areas shall be designed to allow
sufficient and orderly warehousing of
returned or recalled products.
• Segregation shall be provided for the storage
of rejected, recalled or returned materials or
products.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
102
The inspection for compliance
with GMP regulations
• Short description of the self inspection system
indicating whether an outside, independent
and experienced external export was involved
in evaluating the manufacturer’s compliance
with Good manufacturing Practices in all
aspects of production.
• Periodic inspection of the garments shall be
done by responsible staff.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
103
The inspection for compliance
with GMP regulations
• When inspection is done visually, it shall be done
under suitably controlled conditions of illumination
and background.
• Operators doing the inspection shall pass regular
eye-sight checks with spectacles, if worn, and be
allowed frequent rest from inspection.
• Where other methods of inspection are used, the
process shall be validated and the performance of
the equipment checked at suitable intervals. Results
shall be recorded.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
104
The inspection for compliance
with GMP regulations
• Inspection of equipment for cleanliness
immediately before use;
• Clarity testing inspection units.
• Tablet Inspection unit/belt.
• Visual inspection area
• Medical inspection of workers at the time of
employment and periodically check-up thereafter
at least once a year.
• Needle Inspection Unit.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
105
Controlled substances
safeguards
• Hazardous, toxic substances and flammable materials
shall be stored in suitably designed and segregated,
enclosed areas in conformity with Central and State
Legislations.
• Highly hazardous, poisonous and explosive materials
such as narcotics, psychotropic drugs and substances
presenting potential risks of abuse, fire or explosion
shall be stored in safe and secure areas. Adequate fire
protection measures shall be provided in conformity
with the rules of the concerned civic authority.
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
106
References
• EU Good Manufacturing Practice (GMP)
Guidelines, Volume 4 of “The rules governing
medicinal products in the European Union”
• US FDA current Good Manufacturing Practice
(cGMP) for finished pharmaceuticals, 21 CFR, 210
and 211
• WHO Good Manufacturing Practices for
pharmaceutical products, Annex 4 to WHO
Technical Report Series, No. 908, 2003
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
107
E-mail: [email protected]
2014/01/12
Department of Pharmaceutics, Omar AlMukthar University, Al-Bayda, Libya.
108